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ABSTRACT
Background Asthma exacerbations represent a
signiﬁcant disease burden and are commonly caused by
rhinovirus (RV), which is sensed by Toll-like receptors
(TLR) such as TLR7. Some asthmatics have impaired
interferon (IFN) responses to RV, but the underlying
mechanisms of this clinically relevant observation are
poorly understood.
Objectives To investigate the importance of intact
TLR7 signalling in vivo during RV exacerbation using
mouse models of house dust mite (HDM)-induced
allergic airways disease exacerbated by a superimposed
RV infection.
Methods Wild-type and TLR7-deﬁcient (Tlr7−/−) BALB/
c mice were intranasally sensitised and challenged with
HDM prior to infection with RV1B. In some experiments,
mice were administered recombinant IFN or adoptively
transferred with plasmacytoid dendritic cells (pDC).
Results Allergic Tlr7−/− mice displayed impaired IFN
release upon RV1B infection, increased virus replication
and exaggerated eosinophilic inﬂammation and airways
hyper reactivity. Treatment with exogenous IFN or
adoptive transfer of TLR7-competent pDCs blocked these
exaggerated inﬂammatory responses and boosted IFNγ
release in the absence of host TLR7 signalling. TLR7
expression in the lungs was suppressed by allergic
inﬂammation and by interleukin (IL)-5-induced
eosinophilia in the absence of allergy. Subjects with
moderate-to-severe asthma and eosinophilic but not
neutrophilic airways inﬂammation, despite inhaled
steroids, showed reduced TLR7 and IFNλ2/3 expression
in endobronchial biopsies. Furthermore, TLR7 expression
inversely correlated with percentage of sputum
eosinophils.
Conclusions This implicates IL-5-induced airways
eosinophilia as a negative regulator of TLR7 expression
and antiviral responses, which provides a molecular
mechanism underpinning the effect of eosinophil-
targeting treatments for the prevention of asthma
exacerbations.
INTRODUCTION
Asthma is a complex and heterogenic inﬂammatory
disease of the airways with increasing global preva-
lence. The most common trigger for asthma symp-
toms is immune cell activation against innocuous
antigens (allergens) and respiratory viral infections.1
Upon antigen exposure, cytokines such as thymic
stromal lymphopoietin (TSLP), granulocyte-
macrophage colony-stimulating factor, interleukin
(IL)-25, IL-33 and tumour necrosis factor-related
apoptosis-inducing ligand are released by the airway
epithelium, resulting in the activation of innate
immune cells that promote T helper 2 (TH2) cell dif-
ferentiation, leading to the release of TH2 cytokines
such as IL-4, IL-5 and IL-13.1 2 IL-13 is a potent
inducer of airway hyper reactivity (AHR) and mucus
production in a signal transducer and activator of
transcription-6 (STAT6)-dependent manner.3 IL-5
regulates maturation of eosinophils in the bone
marrow and in concert with chemokines such as
eotaxins the recruitment of these cells into the
airways.4 Thus, TH2 cell activation underpins many
clinical phenotypes including allergic and eosino-
philic asthma.5 The proportion of asthmatics with
high eosinophil numbers in their airways represent
the majority of patients, and some of those unre-
sponsive to corticosteroids have severe
therapy-refractory asthma with a disproportionally
large burden of disease. Importantly, they are also
prone to asthma exacerbations, which can be par-
tially alleviated by therapeutics that block IL-4, IL-5
or IL-13 and reduce eosinophilic inﬂammation in
the lungs.5 However, the molecular mechanisms
that link TH2-induced eosinophilia with susceptibil-
ity to exacerbation are yet to be deﬁned.
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Key messages
What is the key question?
▸ What underlies impaired interferon responses
to rhinovirus in asthmatics.
What is the bottom line?
▸ Suppression of Toll-like receptor (TLR)7 by
interleukin-5-induced lung eosinophilia impairs
interferon responses to rhinovirus, leading to
exaggerated inﬂammatory responses and
exacerbation.
Why read on?
▸ This provides a mechanism whereby therapies
modulating TLR7 or targeting eosinophils may
ameliorate virus-induced asthma exacerbations.
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Viral respiratory infections are detected in up to 85% of
asthma exacerbations and two-thirds of those are caused by rhi-
noviruses (RV).6 Notably a group of asthmatics have impaired
release of innate interferons (IFNα, IFNβ and IFNλ) upon
experimental RV infection and IFNλ inversely correlated with
induced sputum eosinophils on day 3 of acute infection.7 8
IFNλ 2/3 inversely correlated with induced sputum eosinophils
on day 3 of the acute infection (r=−0.53, p=0.05), when sub-
jects were experimentally infected with RV16 in vivo.8 RV is
sensed by a limited number of pattern recognition receptors,
including Toll-like receptors (TLRs) and retinoid acid-induced
gene 1 like receptors. TLR3 and TLR7 are endosomally loca-
lised and recognise viral nucleic acids, critically regulating anti-
viral IFN production. Recent studies have shown that impaired
TLR3 function does not affect RV replication in vivo and TLR3
expression is not reduced in asthmatics.9 10 The in vivo role of
functional TLR7 signalling in mounting antiviral responses to
RV has yet to be determined. TLR7 is widely expressed in
innate immune cells such as dendritic cells (DCs) and macro-
phages, as well as in structural lung cells, including airway epi-
thelia.11 Treatment of mice with TLR7 agonists leads to a
long-lasting protection from the development of allergic airways
disease (AAD) and TLR7 activation also reduced airway smooth
muscle contractility in mice.12 We and others have found
reduced IFNα and IFNλ release upon TLR7 stimulation of per-
ipheral blood mononuclear cells from asthmatics and a trend
towards lower TLR7 expression was observed in bronchoalveo-
lar lavage ﬂuid (BALF) cells from asthmatics.9 However, the role




Endobronchial biopsies were obtained by bronchoscopy with
samples taken from third-generation bronchi. Biopsies were
stored in RNALater (Ambion) at −20°C until needed. RNA was
extracted following the miRNeasy Mini Handbook (Qiagen)—
puriﬁcation of total RNA from tissue via homogenisation
(Qiashredder). RNA was quantiﬁed by spectrophotometry
(NanoDrop) and 200 ng of extracted RNA reverse transcribed
using High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems; ABI). The inﬂammatory phenotype was determined
by induced sputum count, and patients with a RAST
ImmunoCAP Speciﬁc IgE-positive blood test were designated as
atopic.
Animals
Wild-type (WT), Tlr7−/−, Tlr4−/−, MyD88−/−, Stat6−/− and IL-5
transgenic mice, all on a BALB/c background (6–14 weeks of
age), were obtained from Australian BioResources (Moss Vale,
Australia) and housed in approved containment facilities within
the HMRI Building, University of Newcastle (Newcastle,
Australia). Mice had ad libitum access to food and water under
a 12 h light and dark cycle. All experiments were approved by
the Animal Care and Ethics Committee of the University of
Newcastle.
Induction of AAD and RV-induced exacerbation
AAD and RV-induced exacerbation were performed as previ-
ously described.13 Brieﬂy, lyophilised crude house dust mite
(HDM) (Dermatophagoides pteronyssinus) extract (Greer
Laboratories) was resuspended in sterile saline (SAL) and intra-
nasally delivered to mice under light isoﬂurane anaesthesia.
Sensitisation on days 0, 1 and 2 (HDM 50 mg/50 mL) was
followed by daily challenge (HDM 5 mg/50 mL) on days 14, 15,
16 and 17 to induce AAD. On day 18, mice were euthanased
via pentobarbital sodium overdose (Virbac) and samples col-
lected. In other experiments, mice were intranasally infected
with live minor group RV (RV1B), 50 mL containing 5×106
virions median tissue culture infective dose (TCID50) or
UV-inactivated RV1B 24 h after last HDM exposure to exacer-
bate pre-existing AAD. Samples were collected 24 h after RV1B
infection.
Administration of recombinant cytokines and LPS
Naive mice were intranasally administered recombinant mouse
IL-13 (15 mg/35 mL; Biolegend), IL-5 (15 mg/35 mL; Biolegend)
or a low or high dose (0.12 mg/50 mL and 10 mg/50 mL ,respect-
ively) of lipopolysaccharide (LPS) (Escherichia coli, 0111:B4;
Sigma-Aldrich), with samples collected 24 h later. HDM-sensitised
and challenged Tlr7−/− mice, which also received live RV1B, were
intranasally administered either recombinant mouse IFNα2
(10 000 IU/50 mL; eBioscience), IFNβ1 (10 000 IU/50 mL;
Biolegend), IFNλ2 (1 mg/50 mL; R&D Systems)14 or a vehicle
control (phosphate buffered saline) on day 18 (2 h following
RV1B infection). Mice were sacriﬁced 24 h postinfection and
samples collected.
AHR measurement
AHR was measured as previously described.15 Brieﬂy, AHR was
invasively assessed in separate groups of anaesthetised mice by
measurement of total lung resistance and dynamic compliance
(Buxco). Mice were mechanically ventilated, and AHR to nebu-
lised methacholine (increased lung resistance) was expressed as a
percentage change from control (baseline).
Analysis of lung inﬂammation
BALF was collected and analysed as previously described.16
Enumeration of peribronchial/perivascular eosinophils and
PAS-positive cells was performed as previously described.17
Flow cytometry
Single lung cell suspensions were prepared and stained as previ-
ously described.18 Antibodies used were FITC-anti-TCRβ chain
(BD, cat. no. 553171, clone H57-597), PE-anti-CD4 (BD, cat.
no. 553652, clone H129.19), PerCP-anti-CD8a (BD, cat. no.
561092, clone 53-6.7), PerCP-Cy5.5-anti-CD11b (BD, cat. no.
561092, clone M1/70), FITC-anti-CD11c (BD, cat. no. 553801,
clone HL3), PE-anti-MHCII (eBioscience, cat. no. 12-5321,
clone M5/114.15.2), all at 1:15 dilution. Positive cells were
identiﬁed using a FACSCanto (BD) by the following criteria:
mDCs—CD11b+ CD11c+ MHCII+; T cells—TCRβ chain+
with CD4+ or CD8a+. Data analysed with BD FACsdiva.
Quantitative RT-PCR
Trachea and lungs were extracted from euthanased mice and
forceps used to separate the airways from the parenchyma by
blunt dissection.19 Total mRNA was extracted using TRIzol
(Ambion; Carlsbad, USA). cDNA was generated via reverse tran-
scription using BioScript (Bioline; Alexandria, Australia).
Quantitative PCRs (qPCR) were performed on cDNA generated
from mouse airway tissue and human endobronchial biopsies
with SYBR Green (Invitrogen; Mulgrave, Australia) using
primers detailed in online supplementary table S1. CTs of the
genes of interest were referenced HPRT or GAPDH for mouse
and human tissue, respectively. All steps were performed accord-
ing to manufacturer’s instructions.
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Generation of BM-derived pDCs and adoptive transfer
WT and TLR7-deﬁcient bone marrow-derived plasmacytoid
DCs (pDCs) were generated as previously described.20 pDCs
were resuspended at 1×107 cells/mL and 0.5×106 pDC were
administered intranasally to allergic Tlr7−/− mice, 2 h prior to
RV1B infection.
Quantiﬁcation of lung cytokines and IFNs
A single lung lobe from each mouse was excised and snap
frozen before being homogenised in buffers recommended in
the manufacturer’s instructions. Levels of IL-5, IL-13, IFNγ (BD
Biosciences; PharMingen), IFNα, IFNβ (Verikine; PBL Assay
Science), CCL7/MCP3 and IFNλ2/3 (R&D Systems) were deter-
mined in clariﬁed lung lysates by ELISA. CCL2/MCP1, CCL3/
MIP1α, CCL4/MIP1β, CXCL9/MIG and CXCL10/IP10 were
measured by employing a Multiplex Immunoassay (Millipore).
All concentrations were normalised to lung weight.
pDC culture and TCID50
Primary mouse pDCs were isolated from pooled WT or
TLR7-deﬁcient spleens via mechanical dissociation and isolation
with PDCA-1 magnetic beads on an AutoMACS platform
(Miltenyi Biotec) according to manufacturer’s instructions.
Following two isolation runs, positively selected cells were
seeded into 96-well plates at 1×106 cells/well and cultured in the
absence or presence of RV1B (multiplicity of infection =5).20
Supernatant was harvested 48 h postinfection and IFN produc-
tion assessed with ELISA. Number of live RV1B virions was
determined by standard TCID50 serial dilution on Hela-H1 cells,
calculated via the Spearman–Karber method.
Statistical analysis
The signiﬁcance of differences between groups was analysed
using Student’s t test, Mann–Whitney test, analysis of variance
or Kruskal–Wallis with Dunn’s test for multiple comparisons as
appropriate using Graphpad Prism 6. A value of p<0.05 is
reported as signiﬁcant. Data are expressed as mean±SEM.
RESULTS
To investigate TLR7 as a regulator of AAD and antiviral
responses in vivo, we repeatedly challenged WT and
TLR7-deﬁcient (Tlr7−/−) mice with HDM, then superimposed
a RV infection to exacerbate their established AAD as described
previously.15 Exposure of allergic Tlr7−/− mice to RV, com-
pared with WT controls, resulted in impaired production of
type I (α, β), II (γ) and III (λ) IFNs with higher RV replication
in the lower airways (ﬁgure 1A,B). This was despite a lack of
an increase in type II (γ) and III (λ) IFNs to RV infection in
allergic WT mice. Deﬁcient IFN responses coincided with
exaggerated AHR (ﬁgure 1C), eosinophilic airways inﬂamma-
tion (ﬁgure 1D,E), accumulation of CD4+, CD8+ and
myeloid (m) DCs but not pDCs in the lungs (ﬁgure 1F), and
production IL-5 and CCL11 (eotaxin-1) (ﬁgure 1G). We also
observed increased levels of the TH2-priming cytokines IL-25
and TSLP in allergic Tlr7−/− mice infected with RV (see online
supplementary ﬁgure S1). CCL2, CCL3, CCL4 and CCL7 but
not CXCL9 and CXCL10 were also increased in the absence
of TLR7 signalling (see online supplementary ﬁgure S2). There
was no change in IL-13 levels or numbers of mucus-producing
cells (see online supplementary ﬁgure S3a), suggesting a novel
and critical role of TLR7 signalling in RV-induced asthma
exacerbation.
Allergic Tlr7−/− mice received recombinant type I and III IFNs
2 h after infection with RV. Notably, one dose of IFNα2, β or λ2
suppressed RV-induced eosinophilic inﬂammation (ﬁgure 2A), as
well as IL-5 and CCL11 production (ﬁgure 2B) but not IL-13
(see online supplementary ﬁgure S3b). All IFN treatments
induced IFN-γ in the lung (ﬁgure 2C) and limited RV replication
(ﬁgure 2D). There was no effect of IFN treatment on TSLP, IL-25
or IL-33 expression (data not shown). Thus IFN treatment pro-
motes IFN-γ release and impairs IL-5 and CCL11 production
and RV replication in the absence of TLR7.
pDCs release large quantities of IFN during viral infection,
and here we show that splenic pDCs exposed to RV in vitro
display impaired release of IFN-α and IFN-β but not λ2/3 in the
absence of TLR7 (ﬁgure 3A). Adoptive transfer of
TLR7-expressing pDCs into allergic Tlr7−/− mice re-established
IFNα, IFNβ and IFNγ but not IFNλ release in the lungs upon RV
infection and limited RV replication as compared to allergic
Tlr7−/− mice that received TLR7-deﬁcient pDCs (ﬁgure 3B, C).
Transfer of WT pDCs also limited RV-induced AHR (ﬁgure 3D),
eosinophilic airways inﬂammation (ﬁgure 3E) and production of
IL-5 and CCL11 (ﬁgure 3F) but not IL-13 release (see online sup-
plementary ﬁgure S3c). Thus adoptive transfer of
TLR7-expressing pDCs—like exogenous IFN treatment—pro-
motes IFNγ release and impairs eosinophilic airways inﬂamma-
tion and RV replication in the absence of TLR7.
TLR7 expression was assessed in a number of knockout
mice strains as it was suppressed in allergic WT mice with
TH2-mediated AAD (ﬁgure 4A). Notably this allergen-induced
reduction in TLR7 expression was not observed in TLR4
(Tlr4−/−), MyD88 (Myd88−/−) or STAT6 (Stat6−/−)-deﬁcient
mice, suggesting that intact TH2-promoting signalling pathways
and the presence of eosinophilic airways inﬂammation are
required for suppression of TLR7. To investigate the speciﬁc
role of TH2 cytokines in this in vivo observation, we delivered
one dose of recombinant IL-13 or IL-5 intranasally to WT
mice and compared those responses to ones challenged with
LPS (a TLR4 agonist). Interestingly, in mice that constitutively
overexpress IL-5 (IL-5Tg/Tg mice) TLR7 expression was signiﬁ-
cantly reduced (ﬁgure 4B) and was associated with accumula-
tion of eosinophils in the airways in the absence of allergy
(ﬁgure 4D). Intranasal administration of one dose of IL-5 or
IL-13, however, had no effect on TLR7 expression or eosino-
phil recruitment although IL-13 did induce AHR and increased
expression of Muc5AC (data not shown). In addition, one low
or high dose of LPS increased TLR7 expression and resulted in
the accumulation of neutrophils but not eosinophils in the
lungs (ﬁgure 4C,D). Thus eosinophilic airways inﬂammation
due to chronic IL-5 release is associated with a reduction in
TLR7 expression while a single administration of IL-5 or IL-13
had no effects on TLR7.
We next analysed TLR7 expression in bronchial biopsies col-
lected from healthy subjects and patients with moderate-to-severe
persistent asthma (clinical and demographic data in online sup-
plementary table S2). Importantly, asthmatics with an eosino-
philic airways inﬂammation, as determined by bronchial
lavage,21 displayed signiﬁcantly reduced TLR7 (ﬁgure 4E) and
IFNλ2/3 expression (ﬁgure 4F), independent of atopic status
(ﬁgure 4G). Furthermore, levels of TLR7 expression positively
correlated with IFNα and λ2/3 expression (ﬁgure 4I–K) and
inversely correlated with percentage of sputum eosinophils
(ﬁgure 4H) but not macrophages or neutrophils (rs=0.04;
p=0.81; n=33 and rs=0.31; p=0.08; n=33, respectively).
These results suggest that suppression of TLR7 and IFN
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expression in moderate-to-severe asthmatics is speciﬁcally tied to
eosinophilic airways inﬂammation in this cohort.
DISCUSSION
Impaired innate IFN responses to respiratory viruses have been
proposed as one mechanism underlying the clinical observation of
asthmatics being susceptible to RV-induced exacerbation.7 8 Innate
IFN responses are instigated by a limited number of pattern recog-
nition receptors, such as TLR7 whose cognate ligands include the
RV viral genome.10 11 Experiments in human immortalised epithe-
lial cell lines (BEAS-2B) have supported a role of TLR3 in mediat-
ing an antiviral and anti-inﬂammatory response.9 However, TLR3
expression in the airways22 and TLR3-induced responses did not
vary in PBMCs derived from asthmatic or atopic patients by com-
parison to healthy subjects.22 We show here, for the ﬁrst time in
vivo, that a lack of TLR7 signalling under conditions that model a
viral asthma exacerbation leads to impaired IFN production and
exaggerated TH2-driven inﬂammation. Our ﬁndings, such as
increased levels of the TH2-priming cytokines IL-25, IL-33 and
TSLP in Tlr7−/− mice, mirror those published by Kaiko et al,23
infecting non-allergic mice with mouse pneumovirus, a mouse
pathogen similar to human respiratory syncytial virus. These
studies suggest that intact TLR7 signalling is required for sufﬁcient
IFN induction and restrainment of proinﬂammatory responses in
the lung.
As TLR7 activation is upstream of IFN production, we
hypothesised that administration of exogenous IFN would
protect allergic Tlr7−/− mice from RV-induced exacerbation. We
observed that treatment with type I or III IFNs resulted in the
Tlr7−/− mice developing a suppressed phenotype similar to that
of the WT controls, whose TLR7 signalling is active. All IFN
treatments induced the release of IFNγ in the lung, with type I
and III IFNs promoting themselves exclusively, indicative of
their known distinct signalling pathways.14
Figure 1 Toll-like receptor (TLR)7-deﬁcient mice experience exaggerated rhinovirus (RV)-induced exacerbation. Allergic wildtype (WT) and
TLR7-deﬁcient mice were inoculated with live or UV-inactivated RV1B, samples collected 24 h post infection. Levels of interferons (A) and interleukin
(IL)-5 (G) in clariﬁed lung homogenates as assessed by ELISA. (B) Lung viral titre in infected mice was quantiﬁed via quantitative RT-PCR (qRT-PCR)
and 50% tissue culture infectious dose (TCID50). (C) Total lung resistance presented as percentage change in response to methacholine (n=4–6 mice
per group). Peribronchial/perivascular eosinophils and cellular inﬁltrates in bronchoalveolar lavage (BAL) ﬂuid enumerated by light microscopy (D and
E). (F) Numbers of lung mDCs and CD4+/CD8+ T cells quantiﬁed by ﬂow cytometry. (G) CCL11 expression in lower airway tissue enumerated by
qRT-PCR and expressed as % increase over WT house dust mite (HDM)+UV group. Results are mean±SEM (n=3–6 mice per group) and are
representative of two independent experiments. *p<0.05, **p<0.01, ***p<0.001 as compared to strain-matched HDM+UV group or otherwise
indicated determined by students t test except for (C) where analysis of variance was used to compare RI curves.
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RV-induced pDC-derived IFN production was dependent
upon intact TLR7 signalling in vitro. Additionally, adoptive
transfer of TLR7-expressing pDCs into allergic Tlr7−/− hosts
re-established type I and II IFN responses, limiting RV
replication and eosinophilic airways inﬂammation. Notably
TLR7 deﬁciency did not impair pDC recruitment into the
lungs. This implicates activation of TLR7 signalling on pDCs
and increasing host IFN release as important therapeutic
Figure 3 Adoptive transfer of Toll-like receptor (TLR)7-competent plasmacytoid dendritic cells (pDCs) to TLR7-deﬁcient mice limits exacerbation of
allergic airways disease (AAD). Puriﬁed Flt3-L-expanded pDCs from TLR7-deﬁcient (−/−) and TLR7-competent (+/+) bone marrow were adoptively
transferred to allergic Tlr7−/− recipients. Mice were inoculated with RV1B 2 h later and endpoints measured 24 h post infection. (A) Spleen-isolated
pDCs were infected in vitro with RV1B and interferon (IFN) release in cell supernatants assessed by ELISA. Levels of IFNs (B), as well as interleukin
(IL)-5 (F) in clariﬁed lung homogenates as assessed by ELISA. Positive-strand RV1B RNA (C) and CCL11 expression (F) from lower airway tissue
quantiﬁed by quantitative RT-PCR. (D) Total lung resistance presented as percentage change in response to methacholine (n=7–8 mice per group).
(E) Eosinophils present in bronchoalveolar lavage (BAL) ﬂuid. Results are mean±SEM (n=3–5 mice per group). *p<0.05, **p<0.01, ***p<0.001
determined by Student’s t test except for (D) where analysis of variance compared the RI curves. All p values as compared to exacerbated mice that
received TLR7-deﬁcient pDCs.
Figure 2 Exogenous interferon can protect Toll-like receptor (TLR)7-deﬁcient mice from rhinovirus (RV)-induced exacerbation. Exacerbated
TLR7-deﬁcient mice received recombinant interferon (IFN)α2 (α), IFNβ (β), IFNλ2 (λ) or a vehicle control (−) 2 h post-RV1B infection on day 18.
Samples were collected 24 h post infection. (A) Eosinophils present in bronchoalveolar lavage (BAL) ﬂuid and per 100 mm2 of lung tissue. Levels of
interleukin (IL)-5 (B) and interferons (C) in clariﬁed lung homogenates as assessed by ELISA. CCL11 expression (B) and viral RV1B RNA (D) in lower
airway tissue was quantiﬁed by quantitative RT-PCR. Results are mean±SEM (n=3–7 mice per group) and are representative of two independent
experiments. *p<0.05, **p<0.01, ***p<0.001 as compared to vehicle control group determined by Student’s t test.
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strategies, either through the use of TLR7 agonists or targeting
pathways upstream of IFN production. Other IFN-producing
cells may also be relevant. We have recently shown that
anti-CCL7 treatment is sufﬁcient to inhibit IRF-7-dependent
IFNβ expression in RV infection, which was associated with
reduced macrophage inﬂammation but not pDC inﬂux.24 This
highlights the complexity of the inﬂammatory and antiviral
immune response on a cellular level, particularly in an allergic
environment.
WTallergic mice with TH2-driven AAD had signiﬁcantly lower
levels of TLR7 expression compared with non-allergic
SAL-treated mice in the absence of RV infection, which is in line
with the pattern seen clinically in non-infected eosinophilic asth-
matics. TLR4 signalling is required for the development of a
robust TH2-mediated allergic airways inﬂammation in response
to HDM extract, which also contains low amounts of endotox-
ins.19 Allergic airways inﬂammation suppresses TLR7 expression,
which is prevented by disruption of TH2-promoting signalling
pathways governed by TLR4, MyD88 and STAT6. In contrast to
allergic mice, TLR4 activation by LPS led to an upregulation of
TLR7 expression in non-allergic mice. Thus the effects of TLR4
signalling on the regulation of TLR7 expression are determined
by the presence or absence of TH2-dominant allergic airways
inﬂammation. Interestingly, LPS also upregulated TLR3
Figure 4 Toll-like receptor (TLR)7 expression is reduced during eosinophilic lung inﬂammation. (A) Wildtype (WT), TLR4−/−, MyD88−/− and Stat6−/−
mice were sensitised and challenged with house dust mite (HDM) over 18 days and gene expression of TLR7 in lower airway tissue was quantiﬁed by
quantitative RT-PCR. TLR7 airway expression in allergic airways as a percentage of sterile saline (SAL) expression for each strain, (B) as well as lung
tissue eosinophils and (C) bronchoalveolar lavage (BAL) ﬂuid neutrophils and eosinophils (D) from rIL-5, rIL-13, IL-5 Tg and lipopolysaccharide
(LPS)-treated mice 24 h post treatment. Results are mean±SEM (n=4–6 mice per group), gene expression in mice expressed as a % compared to
non-allergic SAL-treated wildtype mice. TLR7 (E) and interferon (IFN)λ2/3 (F) expression in bronchial biopsies collected from non-asthmatic (n=13) and
asthmatic (n=20) subjects stratiﬁed into eosinophilic (>3% eosinophils) or non-eosinophilic (<3% eosinophils) phenotypes based on BAL cell counts.
(G) TLR7 expression in bronchial biopsies collected from non-asthmatic (n=13) and asthmatic (n=20) subjects stratiﬁed according to atopic status. Lines
indicate the median, boxes extend from 25th to the 75th percentile, and error bars extend to 10th and 90th percentiles. (H) Correlation between TLR7
expression from bronchial biopsies and percentage of sputum eosinophils. (I–K) Correlations between TLR7 and IFN expression from patient biopsies.
*p<0.05, **p<0.01, ***p<0.001 as determined by Student’s t test (A–D) or Kruskal–Wallis with Dunn’s multiple comparisons test.
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expression in human monocytes, which was critical for antiviral
responses.25 TLR3−/− mice infected with RV1B, however, dis-
played normal type I IFN responses, unchanged viral titres and
reduced inﬂammatory responses.10 This is in marked contrast to
our data generated in allergic TLR7−/− mice and previous data
in non-allergic TLR7−/− mice.20 Further studies are now
required to elucidate the clinical effect of endotoxins on
TLR7-mediated responses in asthma.
In the absence of TH2-dominant allergic airways inﬂamma-
tion, no suppression of TLR7 expression was observed by a
single exposure to IL-13 or IL-5. However, chronic exposure to
IL-5 alone, which is associated with lung eosinophilia and the
development of AHR,26 markedly impaired TLR7 lung expres-
sion in the absence of allergy. This ﬁnding was of clinical rele-
vance because we observed reduced TLR7 expression in
endobronchial biopsies from asthmatic patients with eosino-
philic inﬂammatory proﬁles. Eosinophilic asthmatics also
expressed lower levels of innate IFNs in addition to TLR7, a
difference that was not observed for expression of TLR3, retin-
oic acid-inducible gene I or melanoma differentiation-associated
gene 5.27 These results are congruent with a recent study that
mapped TLR7 expression in the airways of severe asthmatics.28
Our results suggest a reciprocal regulation between
IL-5-induced eosinophilia and TLR7 expression that affects anti-
viral IFN responses to RV (summary illustrated in ﬁgure 5). In
the absence of virus, it has been shown that TLR7 stimulation
with synthetic agonists in vitro resulted in inhibition of IL-5
through IFNγ and Notch signalling pathways in antigen-
presenting cells29 and upregulation of IFNγ production by
memory CD4+ T cells30 and natural killer cells.31 Consistent
with these ﬁndings, we show impaired IFNγ release in the
absence of TLR7 promotes TH2 immune responses, which can
be rescued by type I and III IFN therapy or adoptive transfer of
TLR7-sufﬁcient pDCs. This is directly relevant to subjects with
moderate-to-severe asthma with a predominantly eosinophilic
airways inﬂammation as these individuals have suppressed—but
not fully deﬁcient—TLR7 expression in their lungs, which corre-
lated with reduced IFN expression. Notably, a human monoclo-
nal antibody to IL-5 (mepolizumab) reduced exacerbation
frequency in moderate-to-severe asthmatics with a predominantly
eosinophilic airways inﬂammation,32 a strategy that may be of
speciﬁc beneﬁt to that clinical population as not all asthmatics
appear to exhibit impaired IFN responses to RV.33 Our data
suggest that TLR7 and its downstream signalling pathway limits
TH2 responses in RV-induced asthma exacerbations and may be a
promising therapeutic target for the prevention and treatment of
viral exacerbation in eosinophilic asthmatics.
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inflammatory responses to rhinovirus and is 
Toll-like receptor 7 governs interferon and
Johnston, Paul S Foster, Peter A B Wark and Joerg Mattes
Jie Zhang, Simon Phipps, Darryl Knight, Nathan W Bartlett, Sebastian L 
Luke Hatchwell, Adam Collison, Jason Girkin, Kristy Parsons, Junyao Li,
doi: 10.1136/thoraxjnl-2014-205465
2015 70: 854-861 originally published online June 24, 2015Thorax 
 http://thorax.bmj.com/content/70/9/854






Supplementary material can be found at: 
References
 #BIBLhttp://thorax.bmj.com/content/70/9/854
This article cites 33 articles, 16 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 






To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 4, 2016 - Published by http://thorax.bmj.com/Downloaded from 
